News Sentiment

SKYE sentiment intelligence

Skye Bioscience, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.69 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-1.5% over one week, -12.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend inactive -12.3% over four weeks
Fair value -82.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 30
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 13
Market source 6
simplywall.st 4
The Globe and Mail 3
Stock Titan 3
Stocktwits 2
TradingKey 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 18
Analyst action 5
Regulatory and legal 3
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
TradingView Direct company coverage

Skye Bioscience, Inc. Financial Disclosures & SEC Filings

This page provides a comprehensive list of Skye Bioscience, Inc.'s SEC filings and other crucial corporate documents, including annual and quarterly reports, earnings releases, and corporate presentations. These documents outline the company's financial performance, operational u

Tone
Positive 65/100
Event
Earnings
Published
01 Jul 2026 13:42
Source
TradingView
The National Law Review Direct company coverage

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Skye Bioscience, Inc. (NASDAQ: SKYE) on behalf of investors who purchased securities before November 4, 2024, and still hold them. The investigation seeks to determine if Skye and its officers engaged in

Tone
Negative 19/100
Event
Regulatory and legal
Published
30 Jun 2026 18:39
Source
The National Law Review
TradingView Direct company coverage

Price to sales forward of Skye Bioscience, Inc. – NASDAQ:SKYE

This article provides financial information for Skye Bioscience, Inc. (NASDAQ: SKYE), specifically focusing on its forward price-to-sales ratio. The content appears to be a market data page from TradingView, offering an overview of the company's financials for investors and analy

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Skye Bioscience, Inc. – NASDAQ:SKYE

This article provides the "Price to earnings forward" metric for Skye Bioscience, Inc. (NASDAQ: SKYE) as displayed on TradingView. It notes that the market is closed and no trades have occurred for this specific metric. The content primarily consists of navigation and disclaimer

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Skye Bioscience, Inc. – NASDAQ:SKYE

This article provides financial information for Skye Bioscience, Inc. (NASDAQ: SKYE), specifically focusing on its "Price to book forward" metric. It appears to be a stub or an incomplete financial data page from TradingView, lacking specific numerical data for the metric but ind

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

Skye Bioscience, Inc. Actuals & Estimates (FWB:09R)

This article provides financial actuals and estimates for Skye Bioscience, Inc. (FWB:09R), covering income statement, balance sheet, cash flow, and valuation metrics. It includes analyst price targets, historical stock performance, earnings reports, and other key financial data.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:11
Source
TradingView
TradingView Direct company coverage

SKYE Forecast — Price Target — Prediction for 2027

The article provides a forecast for Skye Bioscience, Inc. (SKYE) stock, including analyst price targets, current stock performance, and financial data. It notes that analysts have a max estimated price target of $20.00 and a min of $2.00, while the stock has seen significant decr

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 15:10
Source
TradingView
The Globe and Mail Direct company coverage

Skye Bioscience Moves Listing to Nasdaq Capital Market

Skye Bioscience (SKYE) has transferred its listing from the Nasdaq Global Market to the Nasdaq Capital Market due to its stockholders' equity falling below the $10 million threshold. The company also faces a compliance issue with Nasdaq's $1.00 minimum bid price rule and has unti

Tone
Negative 29/100
Event
Market update
Published
25 Jun 2026 06:09
Source
The Globe and Mail
TradingView Direct company coverage

Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall

Skye Bioscience (SKYE) will transfer its common stock listing to the Nasdaq Capital Market, effective June 23, 2026, after its stockholders' equity fell below the Nasdaq Global Market's $10 million requirement. The company reported $9,011,804 in equity as of March 31, 2026. Skye

Tone
Negative 38/100
Event
Market update
Published
23 Jun 2026 10:10
Source
TradingView
Stock Titan Direct company coverage

Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices

Skye Bioscience is transferring its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective June 23, 2026, due to non-compliance with the Global Market's minimum stockholders' equity requirement. The company's ticker symbol will remain "SKYE." A

Tone
Negative 28/100
Event
Market update
Published
22 Jun 2026 22:10
Source
Stock Titan
TradingView Direct company coverage

Skye Bioscience, Inc. Stock 12‑Month Price Target Cut to $7.33, Implies 937% Upside

Skye Bioscience, Inc.'s average 12-month price target has been adjusted to $7.33 from $7.71 by 6 analysts, with forecasts ranging from $2 to $20 per share. This new target suggests a significant 937% potential upside based on the June 18 closing price. The consensus rating for th

Tone
Positive 72/100
Event
Analyst action
Published
19 Jun 2026 04:38
Source
TradingView
TradingKey Direct company coverage

Skye Bioscience Inc (SKYE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Skye Bioscience Inc (SKYE), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis indicates a current price momentum score of 4.29, with the stock trading bet

Tone
Negative 14/100
Event
Market update
Published
19 Jun 2026 01:39
Source
TradingKey
TradingKey Direct company coverage

Skye Bioscience Inc (SKYE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Skye Bioscience Inc's (SKYE) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split events. The current stock price and market capitalization a

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 23:38
Source
TradingKey
富途牛牛 Direct company coverage

Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $6

Piper Sandler has reiterated its Buy rating for SKYE BIOSCIENCE INC (SKYE.US) but has adjusted its price target downwards to $6. This revision indicates that while the firm still sees potential for the company, its valuation estimates have been moderated.

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jun 2026 19:40
Source
富途牛牛
Minichart Direct company coverage

Skye Bioscience, Inc. Amends Articles of Incorporation to Increase Authorized Shares – SEC 8-K Filing May 2026

Skye Bioscience, Inc. has amended its Articles of Incorporation to increase its authorized common shares from 100 million to 300 million, a change approved by shareholders on May 26, 2026. This move provides the company with greater flexibility for future capital raising, acquisi

Tone
Neutral 50/100
Event
Market update
Published
31 May 2026 10:09
Source
Minichart
Finviz Direct company coverage

SKYE - Skye Bioscience Inc Stock Price and Quote

This article provides a detailed overview of Skye Bioscience Inc. (SKYE) stock, including its latest financial data, key metrics, analyst ratings, and a chronological list of recent news and press releases. It also includes information about the company's executive team and recen

Tone
Negative 40/100
Event
Analyst action
Published
30 May 2026 17:11
Source
Finviz
Stock Titan Direct company coverage

Skye Bioscience (NASDAQ: SKYE) holders back major share authorization increase

Skye Bioscience's stockholders have approved an amendment to the company's charter, tripling the authorized common shares from 100 million to 300 million. This change, which does not affect current outstanding shares, allows the company more flexibility for future issuances. The

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 20:38
Source
Stock Titan
TradingView Direct company coverage

SKYE: All proposals passed, directors elected, and no stakeholder questions were raised

Skye Bioscience, Inc.'s 2026 Annual General Meeting successfully passed all proposals, including the election of directors, auditor ratification, an increase in authorized shares, and executive compensation. The meeting also established a quorum and concluded without any question

Tone
Positive 66/100
Event
Market update
Published
26 May 2026 17:09
Source
TradingView
marketscreener.com Direct company coverage

Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1

Skye Bioscience, Inc. announced that its cohort review committee has approved the opening of cohort 2 for its clinical trial. This decision was made based on favorable safety data observed in the first four participants treated in cohort 1. The company is actively developing next

Tone
Positive 77/100
Event
Market update
Published
20 May 2026 11:28
Source
marketscreener.com
Investing.com Direct company coverage

Skye Bioscience gets approval to open second cohort in study

Skye Bioscience, Inc. has received approval to open the second cohort of its CBeyond Part C Expansion Study, following a safety review of the first cohort. The study is evaluating nimacimab monotherapy at varying doses for obesity and metabolic health disorders. Investors have re

Tone
Positive 66/100
Event
Regulatory and legal
Published
20 May 2026 11:19
Source
Investing.com
GlobeNewswire Direct company coverage

Skye Announces Cohort Review Committee Approved Opening of

Skye Bioscience, a clinical-stage biotechnology company, announced that its Cohort Review Committee (CRC) has approved the opening of Cohort 2 for the CBeyond Part C Expansion Study. This decision was based on favorable safety data from the first four participants in Cohort 1, wh

Tone
Positive 91/100
Event
Market update
Published
20 May 2026 10:40
Source
GlobeNewswire
The Globe and Mail Direct company coverage

Skye Bioscience Faces Nasdaq Compliance Risk Over Equity

Skye Bioscience (SKYE) has received a notice from Nasdaq stating that the company is out of compliance with the Nasdaq Global Market’s minimum $10 million stockholders’ equity requirement, having reported only $9,011,804. The company has until June 29, 2026, to submit a plan to r

Tone
Negative 29/100
Event
Market update
Published
17 May 2026 00:09
Source
The Globe and Mail